CLCharles Adam Lorentz

Charles Adam Lorentz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Charles Adam Lorentz has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Utilization, Cost, and Subsequent Salvage Treatment of Ablative Therapies for Localized Prostate Cancer in the United States

    by Nikhil T. Sebastian, Dattatraya Patil, Pretesh R. Patel, Ashesh B. Jani, Bruce W. Hershatter, Vishal R. Dhere, Karen D. Godette, Kamran Salari, C. Adam Lorentz, Mohammad Hajiha, et al.

  • Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States

    by Nikhil T. Sebastian, Dattatraya Patil, Pretesh R. Patel, Ashesh B. Jani, Bruce W. Hershatter, Vishal R. Dhere, Karen D. Godette, C. Adam Lorentz, Aaron D. Weiss, Shreyas S. Joshi, et al.

    Background: Radical prostatectomy (RP) and radiotherapy (RT) are standard‐of‐care treatments for localized prostate cancer. The authors studied the utilization and total health care and patient‐incurred costs of RP and RT in the United States using the Merative MarketScan Medicare (Medicare Supplemental and Coordination of Benefits [MDCR]) and Commercial (Commercial Claims and Encounters [CCAE]) databases.Methods: Men were identified who had nonmetastatic prostate cancer treated with RP, external‐beam RT (EBRT), brachytherapy (BT), EBRT combined with BT (EBRT + BT), stereotactic body RT (SBRT), or proton‐beam therapy (PBT) between 2009 and 2022. Year‐to‐year treatment utilization was compared using the Kendall Tau‐b test. Mean total health care and patient out‐of‐pocket costs within 12 months of treatment were compared using the Kruskal–Wallis test.Results: In the MDCR database, 44,937 patients were identified who received treatment with RP (n = 12,879), EBRT (n = 26,193), BT (n = 926), EBRT + BT (n = 4706), PBT (n = 57), or SBRT (n = 176). Between 2009 and 2021, EBRT use increased from 52.5% to 62.2% (p for trend < .001), SBRT increased from 0.4% to 0.5% (p < .001), BT decreased from 3.1% to 1.0% (p < .001), and EBRT + BT decreased from 14.8% to 6.8% (p < 0.001); whereas use remained similar for RP (from 29.1% to 29.4%; p = .82) and PBT (from 0.1% to 0.1%; p = .93). In the CCAE database, 75,626 patients were identified who received treatment with RP (n = 50,278), EBRT (n = 16,985), BT (n = 1243), EBRT + BT (n = 6811), PBT (n = 92), or SBRT (n = 217). EBRT use increased from 20.0% to 24.9% (p < .001), SBRT increased from 0.1% to 0.8% (p < .001), BT decreased from 2.5% to 0.7% (p < .001), and EBRT + BT decreased from 10.6% to 7.4% (p < .001); whereas use remained similar for RP (from 66.8% to 66.1%; p for trend = .82), and PBT (from 0.1% to 0.1%; p for trend = .76). In the MDCR and CCAE databases, PBT had the highest total cost, whereas BT had the lowest.Conclusions: Between 2009 and 2021, there was increasing use of EBRT and SBRT, whereas use of RP remained stable. Although BT was the least costly, its utilization as monotherapy and combined with EBRT declined.


  • Development of Patient-Specific Nomogram to Assist in Clinical Decision-Making for Single Port Versus Multi-Port Robotic Partial Nephrectomy: A Report from the Single Port Advanced Robotic Consortium

    by Nicolas A. Soputro, Kennedy E. Okhawere, Roxana Ramos-Carpinteyro, Ruben Sauer Calvo, Yuzhi Wang, Celeste Manfredi, Elizabeth Snajdar, Michael Raver, Indu Saini, Jaya S. Chavali, et al.

    Objective: To develop a patient-specific algorithm to better guide clinical decision-making when considering between single port (SP) and multi-port (MP) robotic partial nephrectomy (RPN). Materials and Methods: A retrospective review was performed on the institutional review board-approved, prospectively maintained multi-institutional database of the Single Port Advanced Research Consortium to identify all consecutive patients who underwent SP and MP-RPN between 2019 and 2023. Baseline clinicodemographic variables were used to identify the significant predictors of SP-RPN. The significant variables were used to construct a nomogram to predict the likelihood of SP vs MP-RPN. Results: Of the 1021 patients included in our analysis, 189 (18.5%) and 832 (81.5%) underwent SP and MP-RPN, respectively. Statistically significant predictors of SP-RPN included a lower comorbidity profile, a significant abdominal surgical history as characterized by a higher Hostile Abdomen Index, as well as tumors of lower complexity. The nomogram generated using the aforementioned variables demonstrated a reasonable performance with an area under the curve of 0.79. An optimal cutoff point was determined, with likelihood ratios above 0.12 indicating a preference for SP-RPN. Of note, all SP-RPN cases that scored above the 0.12 cutoff exhibited improved perioperative outcomes, including shorter ischemia time and less intraoperative blood loss. Conclusions: In this study, we have devised a novel patient selection nomogram aimed at enhancing clinical decision-making within the expanding repertoire of RPN approaches. The findings highlighted in this study offer valuable guidance to facilitate appropriate patient selection and thereby ensuring favorable perioperative outcomes associated with RPN procedures.


  • Open Access

    PD41-02 NOMOGRAM TO PREDICT RECURRENCE IN NON-METASTATIC RCC WITH THROMBUS USING A MULTI-CENTER CONTEMPORARY SERIES

    by Michael L. Blute, Timothy A. Masterson, Viraj A. Master, Vitaly Margulis, C. Adam Lorentz, Tyler M. Bauman, Jose A. Karam, Christopher G. Wood, E. Jason Abel

    Risk factors for recurrence after surgery for non-metastatic RCC patients with tumor thrombus are poorly defined. The purpose of this study is to develop a clinically relevant nomogram in non-metastatic RCC patients with tumor thrombus using contemporary data from 5 centers to predict disease recurrence following radical nephrectomy and tumor thrombectomy.

  • 524 Preoperative renal artery embolization in renal carcinoma with venous thrombus: Preliminary results of a multicenter study

    by D. Vazquez-Martul Pazos, V.C. Chantada, U. Capitanio, J.A. Carballido, T. Chromecki, G. Ciancio, S. Daneshmand, C.P. Evans, P. Gontero, J. González, et al.

  • Predicting Length of Stay Following Radical Nephrectomy Using the National Surgical Quality Improvement Program Database

    by C. Adam Lorentz, Andrew K. Leung, Austin B. DeRosa, Sebastian D. Perez, Timothy V. Johnson, John F. Sweeney, Viraj A. Master

    Length of stay is frequently used to measure the quality of health care, although its predictors are not well studied in urology. We created a predictive model of length of stay after nephrectomy, focusing on preoperative variables. We used the NSQIP database to evaluate patients older than 18 years who underwent nephrectomy without concomitant procedures from 2007 to 2011. Preoperative factors analyzed for univariate significance in relation to actual length of stay were then included in a multivariable linear regression model. Backward elimination of nonsignificant variables resulted in a final model that was validated in an institutional external patient cohort. Of the 1,527 patients in the NSQIP database 864 were included in the training cohort after exclusions for concomitant procedures or lack of data. Median length of stay was 3 days in the training and validation sets. Univariate analysis revealed 27 significant variables. Backward selection left a final model including the variables age, laparoscopic vs open approach, and preoperative hematocrit and albumin. For every additional year in age, point decrease in hematocrit and point decrease in albumin the length of stay lengthened by a factor of 0.7%, 2.5% and 17.7%, respectively. If an open approach was performed, length of stay increased by 61%. The R(2) value was 0.256. The model was validated in a 427 patient external cohort, which yielded an R(2) value of 0.214. Age, preoperative hematocrit, preoperative albumin and approach have significant effects on length of stay for patients undergoing nephrectomy. Similar predictive models could prove useful in patient education as well as quality assessment.


  • PD35-05 MULTICENTER VALIDATION OF PREDICTIVE MODEL FOR POSTSURGICAL RECURRENCE IN NON-METASTATIC RCC WITH THROMBUS

    by Michael L. Blute, Timothy A. Masterson, Viraj A. Master, Vitaly Margulis, C. Adam Lorentz, Tyler Bauman, Kristin Zorn, Jose A. Karam, Christopher G. Wood, E. Jason Abel

    Risk factors for recurrence after surgery in non-metastatic RCC patients with tumor thrombus are poorly defined. The purpose of this study is to develop and validate a prognostic model to predict recurrence after surgery in non-metastatic RCC with venous thrombus using contemporary data from 5 centers.

  • Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy

    by Derya Tilki, Brian Hu, Hao G. Nguyen, Marc A. Dall’eRa, Roberto Bertini, Joaquín A. Carballido, Thenappan Chandrasekar, Thomas Chromecki, Gaetano Ciancio, Siamak Daneshmand, et al.

    Metastatic renal cell carcinoma can be clinically diverse in terms of the pattern of metastatic disease and response to treatment. We studied the impact of metastasis and location on cancer specific survival. The records of 2,017 patients with renal cell cancer and tumor thrombus who underwent radical nephrectomy and tumor thrombectomy from 1971 to 2012 at 22 centers in the United States and Europe were analyzed. Number and location of synchronous metastases were compared with respect to patient cancer specific survival. Multivariable Cox regression models were used to quantify the impact of covariates. Lymph node metastasis (155) or distant metastasis (725) was present in 880 (44%) patients. Of the patients with distant disease 385 (53%) had an isolated metastasis. The 5-year cancer specific survival was 51.3% (95% CI 48.6-53.9) for the entire group. On univariable analysis patients with isolated lymph node metastasis had a significantly worse cancer specific survival than those with a solitary distant metastasis. The location of distant metastasis did not have any significant effect on cancer specific survival. On multivariable analysis the presence of lymph node metastasis, isolated distant metastasis and multiple distant metastases were independently associated with cancer specific survival. Moreover higher tumor thrombus level, papillary histology and the use of postoperative systemic therapy were independently associated with worse cancer specific survival. In our multi-institutional series of patients with renal cell cancer who underwent radical nephrectomy and tumor thrombectomy, almost half of the patients had synchronous lymph node or distant organ metastasis. Survival was superior in patients with solitary distant metastasis compared to isolated lymph node disease.


  • Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus

    by Derya Tilki, Hao G. Nguyen, Marc A. Dall’eRa, Roberto Bertini, Joaquín A. Carballido, Thomas Chromecki, Gaetano Ciancio, Siamak Daneshmand, Paolo Gontero, Javier Gonzalez, et al.


  • Utility of preoperative inflammatory markers for prognosis in patients with renal cell carcinoma and vena cava tumor thrombus

    by Charles Adam Lorentz, Mohammad A.S. Jafri, Caroline G. Tai, Lindsey A. Herrel, Viraj A. Master